Injury

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against InMode, Innodata, Fox Factory, and X and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, April 8, 2024
Research, Class Action, Growth, Palo Alto Networks, Federation, Defendant, Food and Drug Administration, Dermatology, News, AI, Nature, Silicon, Complaint, P.C, Goldengate, Research and development, Fox Factory, Confidentiality, Injury, Wolfpack, Marketing, Dentist, FDA

InMode is a global provider of aesthetic medical devices and technology, including devices purporting to offer body sculpting and other rejuvenation technologies.

Key Points: 
  • InMode is a global provider of aesthetic medical devices and technology, including devices purporting to offer body sculpting and other rejuvenation technologies.
  • Specifically, Defendants repeatedly touted the demand for InMode’s devices and told investors that those devices were never sold at a discount.
  • The complaint further alleges that when these misleading statements and omissions about Fox Factory’s business reached the market, investors were harmed significantly.
  • For more information on the Palo Alto Networks class action go to: https://bespc.com/cases/PANW

INMD 8-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages InMode Ltd. (INMD) Investors with $100K+ Losses to Contact Firm’s Attorneys Before Apr. 15th Deadline in Securities Class Action

Retrieved on: 
Sunday, April 7, 2024
Injury, SAN, Hagens Berman, FDA, Person, Life insurance

SAN FRANCISCO, April 07, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges InMode Ltd. (NASDAQ: INMD) investors who purchased during the class period and suffered at least $100,000 in losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, April 07, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges InMode Ltd. (NASDAQ: INMD) investors who purchased during the class period and suffered at least $100,000 in losses to submit your losses now .
  • InMode Ltd. (NASDAQ: INMD) Securities Fraud Class Action:
    The complaint alleges that InMode repeatedly touted the demand for its devices and told investors that the devices were never sold at a discount.
  • InMode also assured investors that it had FDA clearance for the current treatments for which it offered its products and that no third-party claims had been brought against it.
  • The truth began to emerge on Feb. 17, 2023, after an investigative publication revealed that InMode customers were threatened with legal action after filing complaints about InMode’s devices and sales tactics.

InMode Ltd. (INMD) Stock Crashes After Report of Severe Discounting, Securities Class Action Filed- Hagens Berman

Retrieved on: 
Thursday, April 4, 2024
Injury, SAN, Hagens Berman, FDA, Person, Life insurance

SAN FRANCISCO, April 04, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges InMode Ltd. (NASDAQ: INMD) investors who purchased during the class period and suffered at least $100,000 in losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, April 04, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges InMode Ltd. (NASDAQ: INMD) investors who purchased during the class period and suffered at least $100,000 in losses to submit your losses now .
  • InMode Ltd. (NASDAQ: INMD) Securities Fraud Class Action:
    The complaint alleges that InMode repeatedly touted the demand for its devices and told investors that the devices were never sold at a discount.
  • InMode also assured investors that it had FDA clearance for the current treatments for which it offered its products and that no third-party claims had been brought against it.
  • “We’re investigating whether InMode made adequate disclosures concerning its pricing, margins and inventory, and about any off-label marketing the company may have engaged in,” said Reed Kathrein, the Hagens Berman partner leading the InMode investigation.

UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on: 
Wednesday, April 3, 2024
Kidney, UHN, User experience, AKI, Patient, Kidney disease, Inflammation, ACTU, Ethics, TMX Group, Pain management, Acute kidney injury, Ischemia, Injury, IRI, Science Advances, Arch, Oxygen, Reperfusion, Placebo-controlled study, Phase, University Health Network, OTCQB, Liver, Yolo Bypass, Randomness

LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Key Points: 
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • The CS-AKI Phase II trial is an international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide.
  • Details of the Phase II trial, entitled “ Phase 2 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of LSALT peptide for the Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery” can be viewed at clinicaltrials.gov .
  • There is no treatment available in the market today that prevents acute kidney injury of the type commonly experienced by on-pump cardiac surgery patients.

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of InMode

Retrieved on: 
Wednesday, April 3, 2024
Food and Drug Administration, LLP, Confidentiality, Injury, Advertising, FDA, Court

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding InMode’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ).

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NYCB, InMode, Innodata, and Fox Factory and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, April 3, 2024
Research, Class Action, Signature, Growth, ACL, Food and Drug Administration, Defendant, Dermatology, News, AI, New York Community Bank, Nature, NYCB, Silicon, Complaint, P.C, Goldengate, Research and development, Fox Factory, Assumption, Confidentiality, Injury, Category, Wolfpack, Dentist, FDA, Marketing

NYCB is a large commercial-real estate lender in the New York City market area, where it specializes in rent-regulated, non-luxury apartment buildings.

Key Points: 
  • NYCB is a large commercial-real estate lender in the New York City market area, where it specializes in rent-regulated, non-luxury apartment buildings.
  • On January 31, 2024, before the market opened, NYCB announced its fiscal fourth quarter 2023 financial results.
  • The complaint further alleges that when these misleading statements and omissions about Fox Factory’s business reached the market, investors were harmed significantly.
  • For more information on the Fox Factory class action go to: https://bespc.com/cases/FOXF

A-GAME Athlete, Mike Davis, Acquires Fourth Consecutive Victory at UFC Vegas 88

Retrieved on: 
Wednesday, April 3, 2024
Electrolyte, Drink, Injury, Honey, UFC, Sodium, Major League Baseball, MMA, Potassium

ORLANDO, Fla., April 03, 2024 (GLOBE NEWSWIRE) -- A-GAME Beverages Inc. ("A-GAME") is pleased to congratulate Mike Davis on his fourth consecutive victory at UFC Vegas 88 on March 16.

Key Points: 
  • ORLANDO, Fla., April 03, 2024 (GLOBE NEWSWIRE) -- A-GAME Beverages Inc. ("A-GAME") is pleased to congratulate Mike Davis on his fourth consecutive victory at UFC Vegas 88 on March 16.
  • This fight marked the first for Davis in 17 months, but he proved his skills were not at all rusty.
  • Davis (11-2 MMA, 4-1 UFC) submitted Nathan Levy (8-1 MMA, 2-1 UFC) within 1 minute and 43 seconds in the second round of the fight with an arm triangle choke.
  • “We are so stoked to have the incredible athlete and mixed martial artist, Mike Davis, representing our brand!

INMD INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that InMode Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Wednesday, April 3, 2024
Food and Drug Administration, Dermatology, Complaint, Confidentiality, Injury, Dentist, FDA, Court, Person

InMode is a global provider of aesthetic medical devices and technology including devices purporting to offer body sculpting and other rejuvenation technologies.

Key Points: 
  • InMode is a global provider of aesthetic medical devices and technology including devices purporting to offer body sculpting and other rejuvenation technologies.
  • Specifically, Defendants repeatedly touted the demand for InMode’s devices and told investors that those devices were never sold at a discount.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

ASSP takes position opposing exploitative child labor

Retrieved on: 
Tuesday, April 2, 2024
Health, Learning, Environment, United, ASSP, ESG, United Nations, Child, Society, International Labour Organization, Workforce, CIH, Injury, Language, CSP, ANSI, Fatality, Toy

The statement from the board of directors declares that ASSP opposes all forms of exploitative child labor and calls on governmental and nongovernmental entities to combat such practices in the U.S. and worldwide.

Key Points: 
  • The statement from the board of directors declares that ASSP opposes all forms of exploitative child labor and calls on governmental and nongovernmental entities to combat such practices in the U.S. and worldwide.
  • “There has been a focus to loosen U.S. child labor laws to help industry combat labor shortages,” Thornton said.
  • With its child labor position set, ASSP will now pursue next steps that include:
    Publishing articles and hosting webinars to educate the occupational safety and health community.
  • Working with other occupational safety and health organizations to help prohibit exploitative child labor.

Gray Television’s BEAT THE ODDS and SportsGrid Launch Partnership for National Syndication of Five Sports Betting Specials

Retrieved on: 
Tuesday, April 2, 2024
Honey, Growth, Ted, Sport, Superbook, Golf, Dan Abrams, College, Association football, KVVU, News, NHL, Tupelo, MLB, Injury, NBA, BEAT, NFL, Television, Casino

The specials will be part of the “BEAT THE ODDS” nationally syndicated sports betting and entertainment television series produced by Tupelo Media Group and KVVU.

Key Points: 
  • The specials will be part of the “BEAT THE ODDS” nationally syndicated sports betting and entertainment television series produced by Tupelo Media Group and KVVU.
  • The specials begin this weekend for college basketball and will also air on dozens of Gray’s television stations.
  • BEAT THE ODDS’ special coverage will feature breaking news, information and expert gambling analysis from five major sporting events in 2024.
  • The SuperBook at the Westgate Las Vegas Resort and Casino will be the title sponsor for these BEAT THE ODDS specials.